Physician profile
Rupal C Mehta
NPI 1093963738
$66,152.96
in general payments reported to CMS, 2019-2025
7 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,165 · 2021: $1,367 · 2022: $18K · 2023: $13K · 2024: $11K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $16K · Travel and Lodging: $1,566 · Food and Beverage: $1,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,899.50 |
| Consulting Fee | $15,987.50 |
| Travel and Lodging | $1,565.80 |
| Food and Beverage | $1,492.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $36,810.54 | 2021-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $12,929.37 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,357.45 | 2025 | Jardiance |
| Akebia Therapeutics INC | $7,164.57 | 2019 | |
| Dr.Reddy'S Laboratories,INC. | $1,849.50 | 2023 | |
| Olympus America INC. | $22.54 | 2023 | Itind System |
| Bayer Healthcare Pharmaceuticals INC. | $18.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupal Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.